{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:28:09Z","timestamp":1771946889351,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U54DA037842"],"award-info":[{"award-number":["U54DA037842"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Fentanyl and other highly potent synthetic opioids\u00a0are the leading cause of opioid overdose deaths in the United States.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was\u00a0an open\u2010label, uncontrolled 12\u2010week outpatient clinical trial to test the feasibility of a single\u2010day induction onto extended\u2010release buprenorphine (BXR) injection treatment for five adults (N\u2009=\u20095) with opioid use disorder using heroin\u2010containing fentanyl. Participants were planned to receive three monthly BXR injections (300, 300, and 100\u2009mg).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After receiving 24\u2009mg sublingual buprenorphine (SL\u2010BUP), all five participants received the BXR 300\u2009mg injection on the first day of induction. All five participants were retained for the full 3\u2010month study period postinduction and received all three scheduled BXR injections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusion<\/jats:title><jats:p>This study provides preliminary evidence supporting the feasibility of inducting users of heroin\u2010containing fentanyl onto BXR 300\u2009mg in a single day.<\/jats:p><\/jats:sec><jats:sec><jats:title>Scientific Significance<\/jats:title><jats:p>The ability to administer a long\u2010acting injection of BXR that assures therapeutic serum levels for a month on the first day of treatment contact is a promising development for the treatment of OUD.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajad.13193","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T10:16:34Z","timestamp":1625480194000},"page":"470-476","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Open\u2010label trial of a single\u2010day induction onto buprenorphine extended\u2010release injection for users of heroin and fentanyl"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9535-7744","authenticated-orcid":false,"given":"John J.","family":"Mariani","sequence":"first","affiliation":[{"name":"Division on Substance Use Disorders New York State Psychiatric Institute  New York New York USA"},{"name":"Department of Psychiatry Columbia University Irving Medical Center  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy L.","family":"Mahony","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders New York State Psychiatric Institute  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel C.","family":"Podell","sequence":"additional","affiliation":[{"name":"Gordon F. Derner School of Psychology Adelphi University  Garden City New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders New York State Psychiatric Institute  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Brezing","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders New York State Psychiatric Institute  New York New York USA"},{"name":"Department of Psychiatry Columbia University Irving Medical Center  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean X.","family":"Luo","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders New York State Psychiatric Institute  New York New York USA"},{"name":"Department of Psychiatry Columbia University Irving Medical Center  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasir H.","family":"Naqvi","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders New York State Psychiatric Institute  New York New York USA"},{"name":"Department of Psychiatry Columbia University Irving Medical Center  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4209-1329","authenticated-orcid":false,"given":"Frances R.","family":"Levin","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders New York State Psychiatric Institute  New York New York USA"},{"name":"Department of Psychiatry Columbia University Irving Medical Center  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"Key Substance Use and Mental Health Indicators in the United States.\u00a0Results from the 2018 National Survey on Drug Use and Health","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2019"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm675152e1"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6712a1"},{"key":"e_1_2_7_5_1","volume-title":"2019 Annual Surveillance Report of Drug\u2010Related Risks and Outcomes\u2014United States\u00a0Surveillance Special Report","author":"Centers for Disease Control and Prevention.\u00a0","year":"2019"},{"key":"e_1_2_7_6_1","series-title":"\u00a0(NCHS Data Brief\u00a0No. 356).\u00a0","volume-title":"Drug Overdose Deaths in the United States, 1999\u20132018","author":"Hedegaard H","year":"2020"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.10.016"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2014.08.010"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0727-z"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90685-W"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2010.12.007"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(93)90152-S"},{"issue":"4","key":"e_1_2_7_13_1","first-page":"848","article-title":"Modulation by mu\u2010opioid agonists of guanosine\u20105\u2032\u2010O\u2010(3\u2010[35S]thio)triphosphate binding to membranes from human neuroblastoma SH\u2010SY5Y cells","volume":"47","author":"Traynor JR","year":"1995","journal-title":"Mol Pharmacol"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.138"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.12.005"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32259-1"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"e_1_2_7_18_1","volume-title":"Unintentional Drug Poisoning (Overdose) Deaths in New York City, 2000 to 2017","author":"Nolan ML","year":"2018"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13018"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5920.656"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.17.2003"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.665"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000434"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.13193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajad.13193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.13193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T21:12:34Z","timestamp":1693343554000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajad.13193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/ajad.13193"],"URL":"https:\/\/doi.org\/10.1111\/ajad.13193","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"2020-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}